JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zahniser, N. R.
Right arrow Articles by Dubocovich, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zahniser, N. R.
Right arrow Articles by Dubocovich, M. L.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*TRITIUM

Comparison of dopamine receptor sites labeled by [3H]-S-sulpiride and [3H]-spiperone in striatum

NR Zahniser and ML Dubocovich

Binding of the radiolabeled active isomer of the neuroleptic sulpiride, [3H]-S-sulpiride, to rat and rabbit striatal membranes was characterized. Regardless of whether the specific binding of [3H]-S- sulpiride was defined with spiperone or the active isomers of butaclamol or flupenthixol, a single homogeneous++ population of binding sites (rat: Kd = 5.6 nM, maximum binding = 590 fmol/mg of protein; rabbit: Kd = 8.3 nM, maximum binding = 540 fmol/mg of protein) was detected. The pharmacological profile of these sites was characteristic of that described for the dopaminergic D-2 receptor subtype. To determine whether [3H]-S-sulpiride and [3H]spiperone label common sites in the striatum, the binding of these two radioligands was compared under similar assay conditions. When specific binding of [3H]spiperone was defined with S-sulpiride, [3H]spiperone labeled the same number of binding sites as [3H]-S-sulpiride despite the fact that the affinity of the sites for [3H]spiperone was 80- to 90-fold higher than for [3H]-S-sulpiride. When specific binding of [3H]spiperone was defined with either (+)-butaclamol or (alpha)-flupenthixol, however, approximately 30% more sites were labeled. The predominant site labeled by [3H]spiperone also possessed the characteristics of the D-2 receptor. It is concluded that [3H]-S-sulpiride under the conditions used is a selective radioligand with which dopamine receptors of the D- 2 subtype can be directly measured and localized. [3H]Spiperone can be used to detect the same sites only if specific binding is defined with S-sulpiride.

Volume 227, Issue 3, pp. 592-599, 12/01/1983
Copyright © 1983 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
A. Iwashita, K. Mihara, S. Yamazaki, S. Matsuura, J. Ishida, H. Yamamoto, K. Hattori, N. Matsuoka, and S. Mutoh
A New Poly(ADP-Ribose) Polymerase Inhibitor, FR261529 [2-(4-Chlorophenyl)-5-quinoxalinecarboxamide], Ameliorates Methamphetamine-Induced Dopaminergic Neurotoxicity in Mice
J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1114 - 1124.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Armstrong and P. G. Strange
Dopamine D2 Receptor Dimer Formation. EVIDENCE FROM LIGAND BINDING
J. Biol. Chem., June 15, 2001; 276(25): 22621 - 22629.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1983 by the American Society for Pharmacology and Experimental Therapeutics.